Cheng-Wen is an accomplished scientific leader having over two decades of experience in ocular drug research and development, from discovery, preclinical, clinical, to marketing authorization. He has expertise in biology, pharmacology, formulation, and drug delivery technologies. He has authored 8 INDs (AR-12286, Latanoprost Implant, PG286, AR-13324, PG324, AR-13503 Implant, AR-1105, and PER-001 Intravitreal Implant), 2 NDAs (Rhopressa^® and Rocklatan^®), and 2 MAAs (Rhokiinsa^TM and Roclanda^TM).

Cheng-Wen Lin is Chief Technology Officer at BRIM Biotechnology, where he is leading their clinical development programs of topical Rho kinase inhibitor for glaucoma and topical tyrosine kinase inhibitor for retinal indications, as well as various preclinical programs for ocular and other indications. He was Chief Scientific Officer at TheratOcular Biotek, where he led the licensing of two ophthalmic products to BRIM Biotechnology.

Prior to TheratOcular, he served as Chief Scientific Officer of Perfuse Therapeutics (San Francisco, CA). He transformed Perfuse from concept to having a nonclinical R&D team with comprehensive capabilities. Prior to Perfuse, he was Head of Research and a founding team member at Aerie Pharmaceuticals (Durham, NC, now Alcon).

Cheng-Wen received his doctorate degree from Duke University and his post-doctorate training from Duke Eye Center (Durham, NC).